BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 8652807)

  • 1. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies.
    Hangaishi A; Ogawa S; Imamura N; Miyawaki S; Miura Y; Uike N; Shimazaki C; Emi N; Takeyama K; Hirosawa S; Kamada N; Kobayashi Y; Takemoto Y; Kitani T; Toyama K; Ohtake S; Yazaki Y; Ueda R; Hirai H
    Blood; 1996 Jun; 87(12):4949-58. PubMed ID: 8652807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia.
    Okuda T; Shurtleff SA; Valentine MB; Raimondi SC; Head DR; Behm F; Curcio-Brint AM; Liu Q; Pui CH; Sherr CJ
    Blood; 1995 May; 85(9):2321-30. PubMed ID: 7727766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
    Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
    Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.
    Ogawa S; Hangaishi A; Miyawaki S; Hirosawa S; Miura Y; Takeyama K; Kamada N; Ohtake S; Uike N; Shimazaki C
    Blood; 1995 Aug; 86(4):1548-56. PubMed ID: 7632963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p16ink4a gene and hematological malignancies.
    Quesnel B; Preudhomme C; Fenaux P
    Leuk Lymphoma; 1996 Jun; 22(1-2):11-24. PubMed ID: 8724524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p16INK4A and p15INK4B gene deletions in primary leukemias.
    Haidar MA; Cao XB; Manshouri T; Chan LL; Glassman A; Kantarjian HM; Keating MJ; Beran MS; Albitar M
    Blood; 1995 Jul; 86(1):311-5. PubMed ID: 7795238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
    Iolascon A; Della Ragione F; Giordani L; Serra A; Saglio G; Faienza MF
    Haematologica; 1998 Sep; 83(9):771-7. PubMed ID: 9825572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas.
    Gombart AF; Morosetti R; Miller CW; Said JW; Koeffler HP
    Blood; 1995 Aug; 86(4):1534-9. PubMed ID: 7632961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia.
    Guo SX; Taki T; Ohnishi H; Piao HY; Tabuchi K; Bessho F; Hanada R; Yanagisawa M; Hayashi Y
    Leuk Res; 2000 Jan; 24(1):39-46. PubMed ID: 10634644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
    Yoshida S; Todoroki T; Ichikawa Y; Hanai S; Suzuki H; Hori M; Fukao K; Miwa M; Uchida K
    Cancer Res; 1995 Jul; 55(13):2756-60. PubMed ID: 7796400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cloning and characterization of murine p16INK4a and p15INK4b genes.
    Quelle DE; Ashmun RA; Hannon GJ; Rehberger PA; Trono D; Richter KH; Walker C; Beach D; Sherr CJ; Serrano M
    Oncogene; 1995 Aug; 11(4):635-45. PubMed ID: 7651726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.
    Drexler HG
    Leukemia; 1998 Jun; 12(6):845-59. PubMed ID: 9639410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
    Elisei R; Shiohara M; Koeffler HP; Fagin JA
    Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia.
    Iravani M; Dhat R; Price CM
    Oncogene; 1997 Nov; 15(21):2609-14. PubMed ID: 9399648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation status analysis of cell cycle regulatory genes (p16INK4A, p15INK4B, p21Waf1/Cip1, p27Kip1 and p73) in natural killer cell disorders.
    Kawamata N; Inagaki N; Mizumura S; Sugimoto KJ; Sakajiri S; Ohyanagi-Hara M; Oshimi K
    Eur J Haematol; 2005 May; 74(5):424-9. PubMed ID: 15813917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma.
    Siebert R; Willers CP; Opalka B
    Leuk Lymphoma; 1996 Nov; 23(5-6):505-20. PubMed ID: 9031081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
    Fujishita T; Mizushima Y; Kashii T; Kobayashi M
    Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.
    Yaginuma Y; Hayashi H; Kawai K; Kurakane T; Saitoh Y; Kitamura S; Sengoku K; Ishikawa M
    Exp Cell Res; 1997 Jun; 233(2):233-9. PubMed ID: 9194486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and clinical significance of CDKN2/MTS1/P16ink4A and MTS2/P15ink4B gene deletions in childhood acute lymphoblastic leukemia.
    Zhou M; Gu L; Yeager AM; Findley HW
    Pediatr Hematol Oncol; 1997; 14(2):141-50. PubMed ID: 9089742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of tumor suppressor genes, Rb, p53, p16INK4A, p15INK4B and p14ARF in natural killer cell neoplasms.
    Sakajiri S; Kawamata N; Egashira M; Mori K; Oshimi K
    Jpn J Cancer Res; 2001 Oct; 92(10):1048-56. PubMed ID: 11676855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.